Abstract
The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60c-src SH2 domain are described. The critical binding interactions between Ac-Tyr-Glu-N(n-C5H11)2 (2) and the protein are established and form the basis for our structure-based drug design efforts. The effects of changes in both the C-terminal (11-27) and N-terminal (51-69) portions of the dipeptide are explored. Analogues with reduced overall charge (92-95) are also investigated. We demonstrate the feasibility of pairing structurally diverse subunits in a modest dipeptide framework with the goal of increasing the druglike attributes without sacrificing binding affinity.
MeSH terms
-
Crystallography, X-Ray
-
Dipeptides / chemical synthesis
-
Dipeptides / chemistry
-
Dipeptides / metabolism
-
Dipeptides / pharmacology*
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / metabolism
-
Enzyme Inhibitors / pharmacology*
-
Enzyme-Linked Immunosorbent Assay
-
Humans
-
Ligands
-
Models, Molecular
-
Molecular Conformation
-
Proto-Oncogene Proteins pp60(c-src) / antagonists & inhibitors*
-
Proto-Oncogene Proteins pp60(c-src) / metabolism
-
Structure-Activity Relationship
-
src Homology Domains*
Substances
-
Dipeptides
-
Enzyme Inhibitors
-
Ligands
-
acetyl-phosphotyrosyl-N,N-dipentylglutamamide
-
Proto-Oncogene Proteins pp60(c-src)